CA2893973A1 - Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii - Google Patents

Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii Download PDF

Info

Publication number
CA2893973A1
CA2893973A1 CA2893973A CA2893973A CA2893973A1 CA 2893973 A1 CA2893973 A1 CA 2893973A1 CA 2893973 A CA2893973 A CA 2893973A CA 2893973 A CA2893973 A CA 2893973A CA 2893973 A1 CA2893973 A1 CA 2893973A1
Authority
CA
Canada
Prior art keywords
mal
ppi
iii
dendrimer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2893973A
Other languages
English (en)
French (fr)
Inventor
Ida FRANIAK-PIETRYGA
Maria BRYSZEWSKA
Dietmar Appelhans
Barbara KLAJNERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Łódź
Original Assignee
University of Łódź
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Łódź filed Critical University of Łódź
Publication of CA2893973A1 publication Critical patent/CA2893973A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C08G83/004—After treatment of dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2893973A 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii Abandoned CA2893973A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL401936A PL234888B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PLP-401936 2012-12-06
PCT/PL2013/000163 WO2014088435A1 (en) 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii

Publications (1)

Publication Number Publication Date
CA2893973A1 true CA2893973A1 (en) 2014-06-12

Family

ID=49955472

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2893973A Abandoned CA2893973A1 (en) 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii

Country Status (9)

Country Link
US (1) US9877985B2 (cg-RX-API-DMAC10.html)
EP (1) EP2928479A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016501261A (cg-RX-API-DMAC10.html)
KR (1) KR20150093216A (cg-RX-API-DMAC10.html)
AU (1) AU2013356793A1 (cg-RX-API-DMAC10.html)
CA (1) CA2893973A1 (cg-RX-API-DMAC10.html)
IL (1) IL239144A0 (cg-RX-API-DMAC10.html)
PL (1) PL234888B1 (cg-RX-API-DMAC10.html)
WO (1) WO2014088435A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL234887B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PL416636A1 (pl) * 2016-03-24 2017-09-25 Univ Łódzki Medyczne zastosowanie dendrymeru polipropylenoiminowego czwartej generacji, opłaszczonego maltotriozą

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208580A1 (en) 2005-09-19 2009-08-20 Regents Of The University Of Michigan Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
US20110177602A1 (en) * 2007-06-27 2011-07-21 Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG Composite Structure
PL234887B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Also Published As

Publication number Publication date
KR20150093216A (ko) 2015-08-17
AU2013356793A1 (en) 2015-07-23
PL234888B1 (pl) 2020-04-30
WO2014088435A1 (en) 2014-06-12
PL401936A1 (pl) 2014-06-09
US20150306134A1 (en) 2015-10-29
EP2928479A1 (en) 2015-10-14
US9877985B2 (en) 2018-01-30
JP2016501261A (ja) 2016-01-18
IL239144A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
Shang et al. Platelet-membrane-camouflaged black phosphorus quantum dots enhance anticancer effect mediated by apoptosis and autophagy
Leanza et al. Direct pharmacological targeting of a mitochondrial ion channel selectively kills tumor cells in vivo
Gutierrez et al. A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulation
Yih et al. Arsenite induces prominent mitotic arrest via inhibition of G 2 checkpoint activation in CGL-2 cells
Zhou et al. Aminated fullerene abrogates cancer cell migration by directly targeting myosin heavy chain 9
Yusuf et al. Liposomal encapsulation of silver nanoparticles (AgNP) improved nanoparticle uptake and induced redox imbalance to activate caspase-dependent apoptosis
Ren et al. Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity
Mameri et al. Oxidative stress as an underlying mechanism of anticancer drugs cytotoxicity on human red blood cells' membrane
Knotigova et al. Application of advanced microscopic methods to study the interaction of carboxylated fluorescent nanodiamonds with membrane structures in THP-1 cells: activation of inflammasome NLRP3 as the result of lysosome destabilization
Ünsal et al. The apoptotic effect of garlic (Allium sativum) derived SEVs on different types of cancer cell lines in vitro
US9877985B2 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III
Zaman et al. DON encapsulated carbon dot–vesicle conjugate in therapeutic intervention of lung adenocarcinoma by dual targeting of CD44 and SLC1A5
Chen et al. An organic free radical generator independent on hydrogen peroxide for chemodynamic and immunotherapy in vivo
Gorojod et al. Nanohydroxyapatite exerts cytotoxic effects and prevents cellular proliferation and migration in glioma cells
US20150320692A1 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
US10022395B2 (en) Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III
Abdulmalek et al. Thymoquinone-conjugated liposomes improve cytotoxic and proapoptotic effects against hepatocellular cancer by altering the EGFR/ERK/MEK signaling axis
Zhang et al. Cancer cell membrane fused liposomal platinum (iv) prodrugs overcome cisplatin resistance in esophageal squamous cell carcinoma chemotherapy
Yerrapragada et al. Treatment of human cells with the anti-cancer drug cisplatin results in the caspase-dependent release of adduct-containing cell-free DNA
Jiang et al. Iterative‐Designed Multifunctional Carbon Dots Nanodrug for Celastrol Loading, Targeting Delivery, and Combination Therapy of Kidney Stones
Kuo et al. Induction of the mitochondria apoptosis pathway by phytohemagglutinin erythroagglutinating in human lung cancer cells
Zuo et al. A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles
Cong et al. Impacts of cationic lipid–DNA complexes on immune cells and hematopoietic cells in vivo
Yulak et al. A PLK1 inhibitor, RO3280, suppresses proliferation of SNU-16 gastric cancer cells via apoptosis
Joma Polyphenolic and polydendritic molecules as modulators of glioblastoma multiforme and its microenvironment

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20191206